Sunshine Biopharma Inc. announced that the exercise price of its outstanding Series B Warrants has been reduced to $1.2202 due to recent sales of common stock under a previously disclosed at-the-market offering, subject to further adjustments. This adjustment impacts the potential dilution and value associated with the company's warrant instruments. The company operates in the biopharmaceutical industry.
